Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 7/20 | 0.47 |
| ▸ | FAAH | O00519 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606381 | 0.89 | HSD17B10 (0.50) | HSD17B10ACHEFAAHBCHEDDB1 | |
| SCHEMBL23120512 | 0.89 | HSD17B10 (0.50) | HSD17B10ACHEFAAHBCHEDDB1 | |
| Hydrochloric Acid SCHEMBL29606388 | 0.88 | HSD17B10 (0.49) | HSD17B10ACHEFAAHBCHEDDB1 | |
| Hydrochloric Acid SCHEMBL23120544 | 0.88 | HSD17B10 (0.49) | HSD17B10ACHEFAAHBCHEDDB1 | |
| SCHEMBL23120553 | 0.88 | DDB1 (0.50) | HSD17B10ACHEFAAHBCHEDDB1 | |
| SCHEMBL29817201 | 0.88 | DDB1 (0.50) | HSD17B10ACHEFAAHBCHEDDB1 | |
| SCHEMBL23120990 | 0.85 | DDB1 (0.43) | DDB1CRBN | |
| Trifluoroacetic Acid SCHEMBL29816949 | 0.85 | DDB1 (0.46) | HSD17B10ACHEFAAHBCHEDDB1 | |
| SCHEMBL23120540 | 0.78 | DDB1 (0.57) | HSD17B10DDB1CRBNSMN1; SMN2KMT2A | |
| SCHEMBL29607604 | 0.78 | DDB1 (0.57) | HSD17B10DDB1CRBNSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | HSD17B10 1399/4885ACHE 2652/4885FAAH 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.